UKSPA Directory 2017 2017-18 - Page 224

224 England | Full Member Stevenage Bioscience Catalyst Stevenage BioScience Catalyst opened as the UK’s first open innovation biomedical campus in 2012, and combines a unique blend of infrastructure and virtual networks to drive collaboration. Backed by Government, GlaxoSmithKline, and Wellcome, the remit is to catalyse innovation for patient benefit. SBC has a strong commitment to companies that focus on high quality science and share its vision. Its development of activity clusters and direct access to the expertise of major pharma are among its unique characteristics. There is start-up and grow-on space for companies, plus a commercially focused management team viewed as a leader in UK incubation. L ocati on Gunnels Wood Road Stevenage SG1 2FX C ontact detai l s Miranda Knaggs Interim CEO T: 01438 906906 E: The concept of SBC was born out of the Government-identified need to better translate academic innovation into commercial reality in the healthcare sector. From the outset, our vision was to catalyse innovation by exploring new ways of collaboration. This vision was embraced and jointly funded by Wellcome, GlaxoSmithKline, and Government. The SBC Incubator opened in 2012 as the UK’s first Open Innovation Campus, bringing together academia, biotech and pharmaceutical companies to advance healthcare research more effectively. In just five years we have incubated more than 60 companies, which have raised between them in excess of £220m of investment, have a 95% tenant survival rate, with 50% planning to expand in the next 12 months. We have attracted inward investment globally, including Japan, Australia, USA, Belgium, Greece, and Italy. innovation and impact We have built our Incubator+ model and its environment around a phenomenally talented and dedicated team. This UKSPA Directory 2017 includes the SBC Board, Management and Operation Teams, GSK Consultancy team Scinovo, the Experts Panel, the >25 mentors and DiscoverAssist team, all of whom have the resounding support of our stakeholders. Our unique focus on innovation and impact has enabled us to build a community of start-ups of which more than 80% are IP-rich and research intensive. These are the types of companies that struggle to make it through the valley of death of early development, and require very specific support and mentorship. SBC is designed to provide that precise environment. working with business We are also home to novel academic industry labs, and the world renowned establishments of the University of Cambridge and University College London have set up a number of translational projects at SBC. As well as engaging with GSK, the residence of the major corporate players GE Healthcare, Lilly, Johnson & Johnson, The GE Technology Lab at the Stevenage Bioscience Catalyst is very well appointed